# Multiple Dose Study to Determine Safety and Tolerability of ESK-001 in Healthy Participants

> **NCT05431634** · PHASE1 · COMPLETED · sponsor: **Alumis Inc** · enrollment: 49 (actual)

## Conditions studied

- Safety and Tolerability

## Interventions

- **DRUG:** Experimental drug: ESK-001
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05431634
- **Lead sponsor:** Alumis Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-05-12
- **Primary completion:** 2022-12-01
- **Final completion:** 2022-12-31
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2023-05-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05431634

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05431634, "Multiple Dose Study to Determine Safety and Tolerability of ESK-001 in Healthy Participants". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05431634. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*